Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$325.84K-$325.84KderivedN/M vs Q4 2021 EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$12,454,428+0.5% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Incomederived-$864,348N/M Operating Cash Flowderived$2,803,484N/M Free Cash Flowderived$2,787,146N/M ended Dec 31, 2022 · filed Mar 10, 2023 · 69 d after period end